Cancer medicine · 2025
Prognostic Value of Massiveness Parameters Measured on Baseline FDG PET in Advanced-Stage Hodgkin Lymphoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Draye-Carbonnier S, Mihailescu S-D, Pinochet P, Texte E, Stamatoullas-Bastard A, Vera P, Becker S, Decazes P
Аннотация
PURPOSE: The prognostic value of radiomic quantitative features measured on pretreatment 18F-FDG PET/CT was investigated in patients with advanced-stage Hodgkin lymphoma (HL).
METHODS: We conducted a retrospective study of 176 HL patients diagnosed between 2006 and 2017. A dozen of PET/CT-derived features were extracted via Oncometer3D from baseline 18F-FDG PET/CT images. The receiver operating characteristic (ROC) curves, Kaplan-Meier method, and Cox analyses were used to assess the prognostic factors for Overall Survival (OS) and Progression-Free Survival (PFS) censored at 5 years.
RESULTS: Four different clusters were identified among the 12 PET parameters analyzed: activity, tumor burden, fragmentation-massiveness, and dispersion. On ROC analyses, medEdgeD, a massiveness parameter, had the highest AUC for OS (0.72) and PFS (0.6). Patients with high baseline medEdgeD had a significantly worse PFS (p = 0.04) and OS (p = 0.003) in both Kaplan-Meier and Cox univariate analyses. Furthermore, medEdgeD remained statistically significant in a multivariate analysis (p = 0.008 for OS and p = 0.014 for PFS) including various TEP and clinical parameters used in daily routine. In addition, in sub-group analyses, a significantly worse prognosis was observed for patients with ABVD and with high baseline medEdgeD value (p = 0.0082 for OS and p = 0.001 for PFS). Moreover, in the bulky subgroup, medEdgeD improved prognostic accuracy (p = 0.016).
CONCLUSION: PET parameters describing massiveness, in particular medEdgeD, are significantly correlated with prognosis in HL patients for OS and PFS, especially when treated with ABVD.
METHODS: We conducted a retrospective study of 176 HL patients diagnosed between 2006 and 2017. A dozen of PET/CT-derived features were extracted via Oncometer3D from baseline 18F-FDG PET/CT images. The receiver operating characteristic (ROC) curves, Kaplan-Meier method, and Cox analyses were used to assess the prognostic factors for Overall Survival (OS) and Progression-Free Survival (PFS) censored at 5 years.
RESULTS: Four different clusters were identified among the 12 PET parameters analyzed: activity, tumor burden, fragmentation-massiveness, and dispersion. On ROC analyses, medEdgeD, a massiveness parameter, had the highest AUC for OS (0.72) and PFS (0.6). Patients with high baseline medEdgeD had a significantly worse PFS (p = 0.04) and OS (p = 0.003) in both Kaplan-Meier and Cox univariate analyses. Furthermore, medEdgeD remained statistically significant in a multivariate analysis (p = 0.008 for OS and p = 0.014 for PFS) including various TEP and clinical parameters used in daily routine. In addition, in sub-group analyses, a significantly worse prognosis was observed for patients with ABVD and with high baseline medEdgeD value (p = 0.0082 for OS and p = 0.001 for PFS). Moreover, in the bulky subgroup, medEdgeD improved prognostic accuracy (p = 0.016).
CONCLUSION: PET parameters describing massiveness, in particular medEdgeD, are significantly correlated with prognosis in HL patients for OS and PFS, especially when treated with ABVD.